Peptidi

Peptide H-DKPTYFE-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.

Peptide H-EKL-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.

Peptide H-QYNVTQAFGR-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.

Peptide H-TGLQEVEVK-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.

A synthetic peptide for use as a blocking control in assays to test for specificity of CTPS antibody, catalog no. 70R-1217

A synthetic peptide for use as a blocking control in assays to test for specificity of ZFYVE28 antibody, catalog no. 70R-8961

Cysteine peptide (Ac RFAAKAA COOH) is used in combination with Lysinepeptide (Ac RFAACAA COOH) in the Direct Peptide Reactivity Assay (DPRA) test.
Direct Peptide Reactivity Assay is used in cosmetic applications for the characterization of the skin sensitizing potential of a substance, framed by OECD Guideline no 442.
The molecular initiating event (MIE) in skin sensitization is a binding between epidermal proteins and the sensitizing chemical substance. MIE is part of the adverse outcome pathway (AOP) of skin sensitization.
It is thanks to the properties of Lysine peptide and Cysteine peptide that the chemical binding will be able to take place, so these synthetic heptapeptides will mimic the reaction of a skin exposed to a substance.
Binding between nucleophilic proteins and electrophile substance will be measured by High Performance Liquid Chromatography (HPLC). Therefore, the decrease in Lysine peptide and Cysteine peptide levels will be a sign of sensitizing event. Depending on the rate of depletion, the sensitizing character of a molecule will be determined (see table at the bottom of the page).
In chemico DPRA test also has wider applications such as hazard classification in cosmetics, but also for pharmaceuticals and biocides. It is a good alternative to animal experimentation.

A synthetic peptide for use as a blocking control in assays to test for specificity of NUDT16L1 antibody, catalog no. 70R-1265

Peptide H-SQVMNLHNL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice.

A synthetic peptide for use as a blocking control in assays to test for specificity of HNRPA0 antibody, catalog no. 70R-1363

A synthetic peptide for use as a blocking control in assays to test for specificity of DYNLL1 antibody, catalog no. 70R-2573

A synthetic peptide for use as a blocking control in assays to test for specificity of ERP29 antibody, catalog no. 70R-6713

A synthetic peptide for use as a blocking control in assays to test for specificity of KIAA0892 antibody, catalog no. 70R-4236

A synthetic peptide for use as a blocking control in assays to test for specificity of COMMD1 antibody, catalog no. 70R-10355

A synthetic peptide for use as a blocking control in assays to test for specificity of GABRA1 antibody, catalog no. 70R-5213

A synthetic peptide for use as a blocking control in assays to test for specificity of RTN2 antibody, catalog no. 70R-1758

Huwentoxin XVI is a synthetic molecule that inhibits the transmission of pain signals. It does this by inhibiting the release of neurotransmitters from dorsal root ganglia cells in the spinal cord. Huwentoxin XVI has been shown to inhibit the cancer-associated inflammatory response, which may be due to its ability to inhibit chronic pain. In addition, Huwentoxin XVI has been shown to have an inhibitory effect on adipose tissue and is thought to be a potential treatment for obesity-associated chronic pain. Huwentoxin XVI also blocks A-type potassium channels, which are responsible for neuronal transmission and are found in neurons and glial cells in the dorsal root ganglia. This inhibition can lead to neuropathic pain or chronic pain caused by nerve damage.

A synthetic peptide for use as a blocking control in assays to test for specificity of PAPOLB antibody, catalog no. 70R-4960

A synthetic peptide for use as a blocking control in assays to test for specificity of ATP8B2 antibody, catalog no. 70R-4519

A synthetic peptide for use as a blocking control in assays to test for specificity of PES1 antibody, catalog no. 70R-3107

A synthetic peptide for use as a blocking control in assays to test for specificity of LEFTY2 antibody, catalog no. 70R-6228

Analog of the native Melan-A (26-35) decapeptide derives from the melanocyte lineage-specific protein Melan-A/MART-1, which is expressed in almost 75-100% of primary and metastatic melanomas.
The region 26-35 of Melan-A protein acts as an antigenic peptide that is recognized by CD8+ tumor-reactive cytolytic T lymphocytes (CTLs) for designing antigen-specific cancer vaccines1. It has been shown that CD8+ Melan-A-specific CTLs isolated from melanoma patients efficiently lyse the Melan-A-expressing HLA-A*0201+ melanoma cell line. However, CTLs preferentially recognize the Melan-A (26-35) peptide as compared with the Melan-A (27-35) peptide. Moreover, the Melan-A (26-35) A27L analog (ELAGIGILTV) has a higher binding affinity to HLA-A*0201 than the native Melan-A (26-35) peptide (EAAGIGILTV), and consequently displays more potent antigenicity and immunogenicity.
It has been reported that the concentration of Melan-A (26-35) A27L analog required to obtain 50% of maximal antigenic activity (EC50) is 0.01nM, whereas that of the native Melan-A (26-35) peptide is 0.25nM1. Therefore, the relative activity of Melan-A (26-35) A27L analog is 25 fold higher than that of the native Melan-A (26-35) peptide.
Furthermore, functional competition assay has shown that the concentration of Melan-A (26-35) A27L analog required to achieve 50% inhibition (IC50) of tumor lysis is 2nM, which is 10 fold lower than that of the native Melan-A (26-35) peptide. Regarding peptide stability in human serum, the half-lifes (t1/2) of the native Melan-A (26-35) peptide and the A27L analog are quite similar (45 and 40min, respectively) as measured by HPLC-ESI-MS, but much higher than that of the Melan-A (27-35) nonapeptide (5min).

A synthetic peptide for use as a blocking control in assays to test for specificity of DNER antibody, catalog no. 20R-1277

A synthetic peptide for use as a blocking control in assays to test for specificity of SCN1B antibody, catalog no. 70R-5206

A synthetic peptide for use as a blocking control in assays to test for specificity of FLJ25791 antibody, catalog no. 70R-3149

A synthetic peptide for use as a blocking control in assays to test for specificity of CALB2 antibody, catalog no. 70R-2905

A synthetic peptide for use as a blocking control in assays to test for specificity of SLCO5A1 antibody, catalog no. 70R-8592

A synthetic peptide for use as a blocking control in assays to test for specificity of PTGDR antibody, catalog no. 70R-10287

A synthetic peptide for use as a blocking control in assays to test for specificity of DUT antibody, catalog no. 70R-1053

A synthetic peptide for use as a blocking control in assays to test for specificity of NRCAM antibody, catalog no. 70R-1741

A synthetic peptide for use as a blocking control in assays to test for specificity of RAD51L1 antibody, catalog no. 70R-9528

A synthetic peptide for use as a blocking control in assays to test for specificity of GAPDHS antibody, catalog no. 70R-3034

A synthetic peptide for use as a blocking control in assays to test for specificity of PARVB antibody, catalog no. 70R-6047

A synthetic peptide for use as a blocking control in assays to test for specificity of MAT2B antibody, catalog no. 70R-3455

A synthetic peptide for use as a blocking control in assays to test for specificity of RTN4IP1 antibody, catalog no. 70R-10138

A synthetic peptide for use as a blocking control in assays to test for specificity of GALE antibody, catalog no. 70R-9266

A synthetic peptide for use as a blocking control in assays to test for specificity of DMAP1 antibody, catalog no. 20R-1081

A synthetic peptide for use as a blocking control in assays to test for specificity of Aldh4a1 antibody, catalog no. 70R-8633

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNK6 antibody, catalog no. 70R-5203

A synthetic peptide for use as a blocking control in assays to test for specificity of PSMB9 antibody, catalog no. 70R-5740

A synthetic peptide for use as a blocking control in assays to test for specificity of ALOX12 antibody, catalog no. 70R-3235

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of ITCH antibody, catalog no. 70R-2367

A synthetic peptide for use as a blocking control in assays to test for specificity of TSPYL6 antibody, catalog no. 70R-1995

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF554 antibody, catalog no. 70R-8121

A synthetic peptide for use as a blocking control in assays to test for specificity of TXNDC13 antibody, catalog no. 70R-7433

A synthetic peptide for use as a blocking control in assays to test for specificity of SMU1 antibody, catalog no. 70R-4370

A synthetic peptide for use as a blocking control in assays to test for specificity of DECR2 antibody, catalog no. 70R-1190

A synthetic peptide for use as a blocking control in assays to test for specificity of C2orf28 antibody, catalog no. 70R-7836

A synthetic peptide for use as a blocking control in assays to test for specificity of C5orf35 antibody, catalog no. 70R-4192

A synthetic peptide for use as a blocking control in assays to test for specificity of IGSF1 antibody, catalog no. 70R-6153

A synthetic peptide for use as a blocking control in assays to test for specificity of EDC4 antibody, catalog no. 70R-4230

A synthetic peptide for use as a blocking control in assays to test for specificity of RHO antibody, catalog no. 70R-9928

A synthetic peptide for use as a blocking control in assays to test for specificity of KRT8 antibody, catalog no. 70R-3263

A synthetic peptide for use as a blocking control in assays to test for specificity of ARFGAP1 antibody, catalog no. 70R-9476

Custom research peptide; min purity 95%.

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of ERMAP antibody, catalog no. 70R-7360

A synthetic peptide for use as a blocking control in assays to test for specificity of IL13RA2 antibody, catalog no. 70R-7514

A synthetic peptide for use as a blocking control in assays to test for specificity of SYMPK antibody, catalog no. 70R-6029

A synthetic peptide for use as a blocking control in assays to test for specificity of Coro2b antibody, catalog no. 70R-9147

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of PCCA antibody, catalog no. 70R-2509

A synthetic peptide for use as a blocking control in assays to test for specificity of GABRB1 antibody, catalog no. 70R-7843

A synthetic peptide for use as a blocking control in assays to test for specificity of TMEM132B antibody, catalog no. 70R-6922

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of SP1 antibody, catalog no. 20R-1138

A synthetic peptide for use as a blocking control in assays to test for specificity of C13orf28 antibody, catalog no. 70R-3516

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of SETD2 antibody, catalog no. 20R-1264

A synthetic peptide for use as a blocking control in assays to test for specificity of ALKBH1 antibody, catalog no. 70R-10379

A synthetic peptide for use as a blocking control in assays to test for specificity of TPPP antibody, catalog no. 70R-10328

A synthetic peptide for use as a blocking control in assays to test for specificity of eve antibody, catalog no. 70R-2549

A synthetic peptide for use as a blocking control in assays to test for specificity of ADSL antibody, catalog no. 70R-9952

A synthetic peptide for use as a blocking control in assays to test for specificity of PRSS21 antibody, catalog no. 70R-9241

A synthetic peptide for use as a blocking control in assays to test for specificity of SSX1 antibody, catalog no. 70R-9559

A synthetic peptide for use as a blocking control in assays to test for specificity of MAGEB4 antibody, catalog no. 70R-4031

A synthetic peptide for use as a blocking control in assays to test for specificity of RORA antibody, catalog no. 70R-1001

A synthetic peptide for use as a blocking control in assays to test for specificity of KLHL20 antibody, catalog no. 70R-9302

Orexin B is a neuropeptide that is produced by a small group of neurons in the hypothalamus, a region of the brain that plays a critical role in regulating various physiological functions, including sleep, appetite, and energy balance.
Orexin B, also known as hypocretin-2, plays a role in promoting wakefulness and arousal. Studies have shown that disruptions in the orexin system are associated with various sleep disorders, including narcolepsy and insomnia. In addition, orexin B has been shown to be involved in the regulation of appetite and energy metabolism, and is being explored as a potential target for the treatment of obesity and other metabolic disorders. Therefore, orexin B is an important neuropeptide and is an active area of research in neuroscience and medicine.

A synthetic peptide for use as a blocking control in assays to test for specificity of STOML3 antibody, catalog no. 70R-7076

A synthetic peptide for use as a blocking control in assays to test for specificity of RPAIN antibody, catalog no. 70R-8518

A synthetic peptide for use as a blocking control in assays to test for specificity of TBX15 antibody, catalog no. 20R-1270

A synthetic peptide for use as a blocking control in assays to test for specificity of BRF1 antibody, catalog no. 70R-8468

A synthetic peptide for use as a blocking control in assays to test for specificity of DIDO1 antibody, catalog no. 70R-8367

The S-100ß ELISA kit is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects the presence of S-100ß protein in serum, plasma, or cerebrospinal fluid. The assay employs an antibody specific for S-100ß protein and an enzyme-labeled anti-IgG antibody as a second antibody to detect bound S-100ß protein.

A synthetic peptide for use as a blocking control in assays to test for specificity of CPEB3 antibody, catalog no. 70R-4412

A synthetic peptide for use as a blocking control in assays to test for specificity of RALA antibody, catalog no. 70R-9415

A synthetic peptide for use as a blocking control in assays to test for specificity of CHIA antibody, catalog no. 70R-5920

A synthetic peptide for use as a blocking control in assays to test for specificity of CEP55 antibody, catalog no. 70R-2148

DBCO-dPEG®12-MAL is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. DBCO-dPEG®12-MAL is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

A synthetic peptide for use as a blocking control in assays to test for specificity of SFRS4 antibody, catalog no. 70R-4842

DOTA-tris(Acid)-Amido-dPEG®4-TFP Ester is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. DOTA-tris(Acid)-Amido-dPEG®4-TFP Ester is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

A synthetic peptide for use as a blocking control in assays to test for specificity of C22orf30 antibody, catalog no. 70R-4259

A synthetic peptide for use as a blocking control in assays to test for specificity of RPL10A antibody, catalog no. 70R-3311

Amyloid β (42- 1) SCR is a peptide that inhibits the interaction of amyloid β with its receptor, which may be useful for research purposes. Amyloid β (42- 1) SCR is an inhibitor that prevents the binding of amyloid β to its receptors. This peptide is a high purity product and has been shown to be effective in inhibiting the interaction between amyloid beta and its receptor.